 Edward Stenehjem
Concepts (206)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antimicrobial Stewardship | 15 | 2025 | 130 | 5.130 |
Why?
| | Hospitals, Community | 7 | 2023 | 67 | 2.720 |
Why?
| | Anti-Bacterial Agents | 23 | 2025 | 1925 | 1.990 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 6 | 2015 | 251 | 1.330 |
Why?
| | Staphylococcal Infections | 5 | 2015 | 393 | 1.200 |
Why?
| | Carrier State | 4 | 2015 | 78 | 1.200 |
Why?
| | Cross Infection | 6 | 2020 | 260 | 1.040 |
Why?
| | Respiratory Tract Infections | 2 | 2023 | 396 | 1.010 |
Why?
| | Ambulatory Care | 9 | 2023 | 610 | 0.650 |
Why?
| | Sinusitis | 1 | 2023 | 227 | 0.630 |
Why?
| | Hospitalization | 16 | 2024 | 2460 | 0.600 |
Why?
| | Drug Resistance, Microbial | 1 | 2018 | 64 | 0.550 |
Why?
| | Anti-Infective Agents | 2 | 2018 | 232 | 0.530 |
Why?
| | Influenza Vaccines | 4 | 2023 | 534 | 0.520 |
Why?
| | Health Plan Implementation | 1 | 2018 | 141 | 0.510 |
Why?
| | Nasal Cavity | 2 | 2015 | 61 | 0.470 |
Why?
| | Drug Utilization | 1 | 2016 | 168 | 0.460 |
Why?
| | Practice Patterns, Physicians' | 6 | 2023 | 1372 | 0.460 |
Why?
| | Community-Acquired Infections | 3 | 2017 | 177 | 0.450 |
Why?
| | Humans | 64 | 2025 | 145763 | 0.420 |
Why?
| | Veterans | 3 | 2015 | 1642 | 0.380 |
Why?
| | Population Surveillance | 2 | 2015 | 484 | 0.380 |
Why?
| | Inappropriate Prescribing | 3 | 2023 | 66 | 0.370 |
Why?
| | Asymptomatic Infections | 1 | 2012 | 37 | 0.370 |
Why?
| | Influenza, Human | 3 | 2023 | 624 | 0.360 |
Why?
| | Ventriculostomy | 1 | 2012 | 24 | 0.360 |
Why?
| | Bacteriological Techniques | 1 | 2012 | 66 | 0.350 |
Why?
| | Drug Resistance, Bacterial | 6 | 2020 | 185 | 0.350 |
Why?
| | Utah | 4 | 2024 | 80 | 0.340 |
Why?
| | Vaccines, Synthetic | 5 | 2022 | 137 | 0.340 |
Why?
| | Bacterial Infections | 2 | 2019 | 246 | 0.340 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2012 | 104 | 0.340 |
Why?
| | Adult | 30 | 2025 | 40872 | 0.340 |
Why?
| | Central Nervous System Diseases | 1 | 2012 | 74 | 0.340 |
Why?
| | Mycoses | 1 | 2012 | 88 | 0.330 |
Why?
| | Prostheses and Implants | 1 | 2012 | 137 | 0.330 |
Why?
| | Sepsis | 3 | 2024 | 664 | 0.310 |
Why?
| | Gram-Negative Bacterial Infections | 2 | 2025 | 49 | 0.310 |
Why?
| | Immunization, Secondary | 4 | 2022 | 92 | 0.310 |
Why?
| | Polymerase Chain Reaction | 1 | 2012 | 1043 | 0.290 |
Why?
| | Emergency Service, Hospital | 11 | 2024 | 2383 | 0.280 |
Why?
| | Outpatients | 2 | 2023 | 447 | 0.270 |
Why?
| | RNA, Messenger | 7 | 2024 | 2805 | 0.270 |
Why?
| | Idaho | 2 | 2018 | 15 | 0.260 |
Why?
| | Delivery of Health Care | 3 | 2023 | 947 | 0.250 |
Why?
| | United States | 14 | 2023 | 16123 | 0.240 |
Why?
| | Research Design | 2 | 2025 | 1139 | 0.240 |
Why?
| | Vaccination | 6 | 2024 | 1428 | 0.240 |
Why?
| | Ambulatory Care Facilities | 3 | 2021 | 269 | 0.230 |
Why?
| | Middle Aged | 21 | 2025 | 36302 | 0.220 |
Why?
| | Hospitals | 4 | 2023 | 733 | 0.220 |
Why?
| | Candidemia | 1 | 2024 | 16 | 0.220 |
Why?
| | Candida | 1 | 2024 | 46 | 0.210 |
Why?
| | Pneumonia, Bacterial | 2 | 2016 | 113 | 0.210 |
Why?
| | Aged | 17 | 2025 | 26215 | 0.200 |
Why?
| | Laboratories | 2 | 2021 | 110 | 0.200 |
Why?
| | Aged, 80 and over | 9 | 2024 | 8346 | 0.200 |
Why?
| | Bacteremia | 1 | 2025 | 222 | 0.190 |
Why?
| | Hospitals, Veterans | 2 | 2015 | 258 | 0.180 |
Why?
| | Telemedicine | 2 | 2024 | 966 | 0.180 |
Why?
| | Male | 22 | 2025 | 73003 | 0.180 |
Why?
| | Viral Vaccines | 1 | 2023 | 107 | 0.180 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2023 | 159 | 0.170 |
Why?
| | Female | 22 | 2025 | 79035 | 0.170 |
Why?
| | Case-Control Studies | 6 | 2023 | 3634 | 0.160 |
Why?
| | Adolescent | 12 | 2024 | 22573 | 0.160 |
Why?
| | Language | 1 | 2023 | 324 | 0.160 |
Why?
| | Cohort Studies | 3 | 2023 | 6032 | 0.160 |
Why?
| | Immunocompromised Host | 1 | 2021 | 202 | 0.150 |
Why?
| | Checklist | 2 | 2018 | 110 | 0.150 |
Why?
| | Clostridium Infections | 1 | 2020 | 74 | 0.140 |
Why?
| | Cooperative Behavior | 2 | 2020 | 463 | 0.140 |
Why?
| | Community-Based Participatory Research | 1 | 2020 | 168 | 0.140 |
Why?
| | Vaccines, Combined | 3 | 2023 | 49 | 0.140 |
Why?
| | Hospital Bed Capacity | 1 | 2018 | 27 | 0.140 |
Why?
| | Risk Factors | 7 | 2024 | 10917 | 0.140 |
Why?
| | Immunization | 1 | 2020 | 375 | 0.140 |
Why?
| | Drug Utilization Review | 1 | 2018 | 61 | 0.140 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2022 | 440 | 0.130 |
Why?
| | Health Services Research | 1 | 2020 | 391 | 0.130 |
Why?
| | Inservice Training | 1 | 2018 | 118 | 0.130 |
Why?
| | Random Allocation | 1 | 2018 | 365 | 0.130 |
Why?
| | Retrospective Studies | 7 | 2024 | 17325 | 0.130 |
Why?
| | Cluster Analysis | 1 | 2018 | 501 | 0.120 |
Why?
| | Young Adult | 6 | 2024 | 14251 | 0.120 |
Why?
| | Documentation | 1 | 2018 | 199 | 0.120 |
Why?
| | Adaptation, Physiological | 1 | 2020 | 560 | 0.120 |
Why?
| | Mass Screening | 3 | 2013 | 1361 | 0.110 |
Why?
| | Pharmacists | 1 | 2018 | 258 | 0.110 |
Why?
| | Patient Readmission | 2 | 2021 | 772 | 0.110 |
Why?
| | Electrophoresis, Gel, Pulsed-Field | 1 | 2015 | 22 | 0.110 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 391 | 0.110 |
Why?
| | Coronavirus Infections | 1 | 2020 | 384 | 0.110 |
Why?
| | Molecular Epidemiology | 1 | 2015 | 74 | 0.110 |
Why?
| | Feasibility Studies | 1 | 2019 | 1115 | 0.110 |
Why?
| | Mental Disorders | 1 | 2024 | 1169 | 0.110 |
Why?
| | Physicians | 1 | 2023 | 956 | 0.100 |
Why?
| | Hospital Mortality | 3 | 2023 | 1038 | 0.100 |
Why?
| | Leadership | 1 | 2018 | 402 | 0.100 |
Why?
| | Program Evaluation | 1 | 2018 | 944 | 0.100 |
Why?
| | Vitamin D Deficiency | 1 | 2015 | 190 | 0.100 |
Why?
| | Isoniazid | 1 | 2013 | 70 | 0.100 |
Why?
| | Medical Staff, Hospital | 1 | 2013 | 80 | 0.100 |
Why?
| | Prospective Studies | 7 | 2022 | 8075 | 0.090 |
Why?
| | Georgia | 1 | 2012 | 79 | 0.090 |
Why?
| | Bacterial Load | 1 | 2012 | 67 | 0.090 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2013 | 127 | 0.090 |
Why?
| | Cross-Sectional Studies | 2 | 2022 | 5922 | 0.090 |
Why?
| | Coinfection | 1 | 2013 | 143 | 0.090 |
Why?
| | Infection Control | 1 | 2013 | 173 | 0.090 |
Why?
| | Intensive Care Units | 2 | 2021 | 924 | 0.090 |
Why?
| | Primary Prevention | 1 | 2013 | 222 | 0.090 |
Why?
| | Antitubercular Agents | 1 | 2013 | 208 | 0.090 |
Why?
| | Nursing Staff, Hospital | 1 | 2013 | 143 | 0.090 |
Why?
| | Prostatic Neoplasms | 2 | 2017 | 981 | 0.090 |
Why?
| | Catheter-Related Infections | 1 | 2012 | 96 | 0.080 |
Why?
| | Pneumonia | 1 | 2017 | 636 | 0.080 |
Why?
| | Gram-Negative Bacteria | 1 | 2011 | 80 | 0.080 |
Why?
| | Decision Support Systems, Clinical | 1 | 2015 | 273 | 0.080 |
Why?
| | Logistic Models | 3 | 2025 | 2139 | 0.080 |
Why?
| | Tuberculosis | 1 | 2013 | 284 | 0.080 |
Why?
| | Risk | 1 | 2012 | 923 | 0.080 |
Why?
| | Occupational Exposure | 1 | 2013 | 355 | 0.080 |
Why?
| | Virulence Factors | 1 | 2011 | 175 | 0.080 |
Why?
| | Recurrence | 1 | 2012 | 1139 | 0.070 |
Why?
| | Administration, Oral | 2 | 2025 | 867 | 0.070 |
Why?
| | Deep Brain Stimulation | 1 | 2012 | 220 | 0.070 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2013 | 1420 | 0.070 |
Why?
| | Models, Biological | 1 | 2014 | 1764 | 0.060 |
Why?
| | Longitudinal Studies | 1 | 2015 | 2967 | 0.060 |
Why?
| | Sensitivity and Specificity | 1 | 2012 | 2000 | 0.060 |
Why?
| | Incidence | 1 | 2012 | 2933 | 0.060 |
Why?
| | Candida tropicalis | 1 | 2024 | 4 | 0.060 |
Why?
| | Administration, Intravenous | 1 | 2025 | 172 | 0.050 |
Why?
| | Immunity, Herd | 1 | 2024 | 7 | 0.050 |
Why?
| | Ethiopia | 2 | 2013 | 44 | 0.050 |
Why?
| | Child, Preschool | 4 | 2023 | 11868 | 0.050 |
Why?
| | Child | 6 | 2023 | 22739 | 0.050 |
Why?
| | Spermine | 1 | 2023 | 29 | 0.050 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2023 | 50 | 0.050 |
Why?
| | Clinical Protocols | 1 | 2024 | 280 | 0.050 |
Why?
| | Predictive Value of Tests | 2 | 2022 | 2123 | 0.050 |
Why?
| | RNA, Messenger, Stored | 1 | 2022 | 7 | 0.050 |
Why?
| | Practice Guidelines as Topic | 2 | 2025 | 1582 | 0.050 |
Why?
| | Propensity Score | 1 | 2025 | 377 | 0.050 |
Why?
| | Kaplan-Meier Estimate | 1 | 2024 | 971 | 0.040 |
Why?
| | Time-to-Treatment | 1 | 2024 | 251 | 0.040 |
Why?
| | Quality Improvement | 2 | 2025 | 1296 | 0.040 |
Why?
| | Vaccination Coverage | 1 | 2023 | 102 | 0.040 |
Why?
| | Proportional Hazards Models | 1 | 2024 | 1330 | 0.040 |
Why?
| | Contraindications | 1 | 2020 | 90 | 0.040 |
Why?
| | Seasons | 1 | 2023 | 538 | 0.040 |
Why?
| | Computer Simulation | 1 | 2025 | 1003 | 0.040 |
Why?
| | Immunization Schedule | 1 | 2021 | 186 | 0.040 |
Why?
| | Clindamycin | 1 | 2020 | 14 | 0.040 |
Why?
| | Daptomycin | 1 | 2020 | 18 | 0.040 |
Why?
| | Carbapenems | 1 | 2020 | 27 | 0.040 |
Why?
| | Fluoroquinolones | 1 | 2020 | 44 | 0.040 |
Why?
| | Cephalosporins | 1 | 2020 | 45 | 0.040 |
Why?
| | Doxycycline | 1 | 2020 | 62 | 0.040 |
Why?
| | Policy | 1 | 2020 | 149 | 0.040 |
Why?
| | Risk Assessment | 2 | 2022 | 3752 | 0.040 |
Why?
| | Pilot Projects | 1 | 2024 | 1897 | 0.040 |
Why?
| | Information Dissemination | 1 | 2020 | 224 | 0.030 |
Why?
| | HIV Infections | 1 | 2013 | 3195 | 0.030 |
Why?
| | Betacoronavirus | 1 | 2020 | 289 | 0.030 |
Why?
| | Drug Prescriptions | 1 | 2019 | 288 | 0.030 |
Why?
| | Antiviral Agents | 1 | 2022 | 769 | 0.030 |
Why?
| | Health Personnel | 1 | 2023 | 757 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 6085 | 0.030 |
Why?
| | Quality of Health Care | 1 | 2020 | 693 | 0.030 |
Why?
| | Clinical Audit | 1 | 2015 | 14 | 0.030 |
Why?
| | Electronic Mail | 1 | 2015 | 60 | 0.030 |
Why?
| | Mortality | 1 | 2017 | 380 | 0.030 |
Why?
| | Odds Ratio | 1 | 2017 | 1083 | 0.030 |
Why?
| | Statistics as Topic | 1 | 2015 | 283 | 0.030 |
Why?
| | Hand Sanitizers | 1 | 2013 | 2 | 0.030 |
Why?
| | Hand Dermatoses | 1 | 2013 | 7 | 0.030 |
Why?
| | Hand Hygiene | 1 | 2013 | 9 | 0.030 |
Why?
| | Patient Isolation | 1 | 2013 | 20 | 0.020 |
Why?
| | World Health Organization | 1 | 2013 | 104 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1547 | 0.020 |
Why?
| | Masks | 1 | 2013 | 70 | 0.020 |
Why?
| | Reminder Systems | 1 | 2013 | 140 | 0.020 |
Why?
| | Time Factors | 2 | 2022 | 7133 | 0.020 |
Why?
| | Pandemics | 1 | 2020 | 1711 | 0.020 |
Why?
| | Neisseria meningitidis | 1 | 2011 | 23 | 0.020 |
Why?
| | Databases, Factual | 1 | 2017 | 1491 | 0.020 |
Why?
| | Quality Indicators, Health Care | 1 | 2013 | 336 | 0.020 |
Why?
| | Immune Evasion | 1 | 2011 | 61 | 0.020 |
Why?
| | Bacterial Toxins | 1 | 2011 | 108 | 0.020 |
Why?
| | Bacterial Adhesion | 1 | 2011 | 109 | 0.020 |
Why?
| | Locomotion | 1 | 2011 | 101 | 0.020 |
Why?
| | Virulence | 1 | 2011 | 278 | 0.020 |
Why?
| | Pregnancy | 1 | 2022 | 7215 | 0.020 |
Why?
| | Guideline Adherence | 1 | 2013 | 587 | 0.020 |
Why?
| | Critical Illness | 1 | 2015 | 900 | 0.020 |
Why?
| | Patient Education as Topic | 1 | 2013 | 777 | 0.020 |
Why?
| | Rectum | 1 | 1988 | 182 | 0.010 |
Why?
| | Physical Examination | 1 | 1988 | 244 | 0.010 |
Why?
| | Attitude of Health Personnel | 1 | 2013 | 1197 | 0.010 |
Why?
| | Health Services Accessibility | 1 | 2013 | 1101 | 0.010 |
Why?
| | Abdominal Injuries | 1 | 1985 | 130 | 0.010 |
Why?
| | Wounds, Nonpenetrating | 1 | 1985 | 321 | 0.010 |
Why?
| | Norway | 1 | 1988 | 41 | 0.000 |
Why?
| | Prognosis | 1 | 1985 | 4329 | 0.000 |
Why?
|
|
Stenehjem's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|